Reports Q3 revenue $3.7M, consensus $4.87M. “The third quarter was one of the most exciting and transformational periods in Zevra’s journey,” said Neil F. McFarlane, Zevra’s President and Chief Executive Officer. “After years of tireless effort, our team has achieved a major milestone with FDA approval of MIPLYFFA(TM) (arimoclomol), and we’re celebrating with the Niemann-Pick disease type C (NPC) community. We intend to achieve our goals with a high-performing team committed to execute, focus and innovate to drive our continued growth and long-term transformation.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- William Blair pharmaceuticals analysts hold analyst/industry conference call
- ZVRA Upcoming Earnings Report: What to Expect?
- Zevra Therapeutics, NUCDF launch check ammonia campaign
- Zevra Therapeutics initiated with a Buy at Guggenheim
- Zevra Therapeutics price target raised to $21 from $19 at Roth MKM